Publications by authors named "B Fleige"
[This corrects the article DOI: 10.1055/a-1298-3453.].
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on breast cancer patients receiving neoadjuvant chemotherapy (NACT) and examines how certain clinical and pathological characteristics relate to residual axillary involvement after treatment.
- The analysis included 360 patients with clinically occult nodal metastases, identifying that 22.3% still had involved lymph nodes after NACT and 22.3% achieved a pathological complete remission (pCR) in the breast.
- Significant associations were found between factors like extranodal spread, absence of multifocality, and pCR in the breast with residual axillary disease; notably, triple-negative and HER/2 positive patients showed a very low risk of residual axillary involvement if they achieved a breast pCR.
Background: Prediction of non-sentinel lymph node (SLN) status after primary systemic therapy (PST) may allow tailored axillary staging. The aim of this analysis was to compare established nomograms from i) the primary operative (n = 6) and ii) the neoadjuvant (n = 1) setting with an optimized nomogram to predict non-SLN status in patients after PST.
Methods: 181 patients converting from cN1 prior to PST to ycN0 but found to have a histologically positive SLN in the SENTINA trial were analyzed.
Optimization of axillary staging among patients converting from clinically node-positive disease to clinically node-negative disease through primary systemic therapy is needed. We aimed at developing a nomogram predicting the probability of positive axillary status after chemotherapy based on clinical/pathological parameters. Patients from study arm C of the SENTINA trial were included.
View Article and Find Full Text PDF